B. Riley downgraded Mirati Therapeutics (MRTX) to Neutral from Buy with a price target of $60, down from $65, after Bristol Myers Squibb (BMY) said it will acquire Mirati for $58 per share plus a contingent value right of $12 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics downgraded to Hold from Buy at JonesResearch
- Mirati Therapeutics downgraded to Hold from Buy at Jefferies
- Mirati downgraded to Market Perform from Outperform at JMP Securities
- Bristol Myers (NYSE:BMY) Boosts Oncology Portfolio with $5.8B Mirati Deal
- Bristol Myers to acquire Mirati Therapeutics for $58 per share